BeOne Medicines Ltd
243 hedge funds and large institutions have $15.7B invested in BeOne Medicines Ltd in 2020 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 114 increasing their positions, 55 reducing their positions, and 15 closing their positions.
463% more call options, than puts
Call options by funds: $46.9M | Put options by funds: $8.32M
167% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 15
107% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 55
66% more capital invested
Capital invested by funds: $9.45B → $15.7B (+$6.26B)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
10% more funds holding
Funds holding: 220 → 243 (+23)
0.31% less ownership
Funds ownership: 5% → 4.69% (-0.31%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$380M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$358M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$261M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$44.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$44.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$85.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$69.5M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$60.4M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$42.2M |
| 5 |
VanEck Associates
New York
|
-$17.8M |
ONC Hedge Fund Activity: Q3 2020 in Review
243 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q3 2020, worth a combined $15.7B — up 66% from $9.45B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ONC positions and 15 closed out — a net gain of 25 holders — while 114 added to existing stakes and 55 trimmed.
The largest buyer was Primecap Management, adding an estimated $380M. The largest seller was Fidelity Investments, cutting an estimated $85.9M.
- 243 institutional investors held BeOne Medicines Ltd (ONC) as of Q3 2020, up from 220 in Q2 2020.
- Funds reported $15.7B of BeOne Medicines Ltd stock for Q3 2020, up 66% quarter-over-quarter.
- 40 funds opened new BeOne Medicines Ltd positions in Q3 2020 and 15 closed out, a net change of +25 holders.
- The largest BeOne Medicines Ltd buyer in Q3 2020 was Primecap Management, an estimated $380M added.
- The largest BeOne Medicines Ltd seller in Q3 2020 was Fidelity Investments, an estimated $85.9M sold.
Based on aggregated 13F filings for Q3 2020.